NEWS HIGHLIGHTS
Published Studies Related to Ca-Dtpa (Pentetate)
Predicting survival and early clinical response to primary chemotherapy for patients with locally advanced breast cancer using DCE-MRI. [2009.06]
PURPOSE: To evaluate dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) as a tool for early prediction of response to neoadjuvant chemotherapy (NAC) and 5-year survival in patients with locally advanced breast cancer... CONCLUSION: DCE-MRI in locally advanced breast cancer has the potential to predict 5-year survival in a small patient cohort. In addition, changes in tumor vascularization after one cycle of NAC can be assessed.
Multicenter, double-blind, randomized, intra-individual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine in MRI of brain tumors at 3 tesla. [2009.04]
PURPOSE: To prospectively compare 0.1 mmol/kg doses of gadobenate dimeglumine and gadopentetate dimeglumine for contrast-enhanced MRI of brain lesions at 3 Tesla (T)... CONCLUSION: Brain lesion depiction at 3T is significantly improved with 0.1 mmol/kg gadobenate dimeglumine.
First-pass dynamic contrast-enhanced MRI with extravasating contrast reagent: evidence for human myocardial capillary recruitment in adenosine-induced hyperemia. [2009.02]
Human myocardial (1)H(2)O T(1)-weighted dynamic contrast-enhanced MRI data were acquired during the brief first-pass period after injection of a very small gadolinium diethylenetriaminepenta-acetate (GdDTPA(2-)) dose. The shutter-speed pharmacokinetic effects of both transendothelial and transcytolemmal equilibrium water exchange processes were investigated...
Contrast-enhanced ultrasound in monitoring the efficacy of a bradykinin receptor 2 antagonist in painful knee osteoarthritis compared with MRI. [2009.01]
OBJECTIVES: To evaluate contrast-enhanced ultrasound (CE-US) as a monitoring tool to assess hypervascularisation of synovial processes in knee osteoarthritis (OA) treated with intra-articular injections of the bradykinin-receptor 2 antagonist icatibant compared to contrast-enhanced magnetic resonance imaging (CE-MRI)... CONCLUSIONS: Our results show that CE-US and CE-MRI have good agreement in assessing inflammatory changes in knee OA. For the 41 patients with OA, an analgesic effect of icatibant could clearly be shown, especially for pain during activity in the high dose icatibant group. However, we could not find an anti-inflammatory effect of icatibant by CE-US compared to CE-MRI.
Low injection rate for 3D moving-table bolus-chase MR angiography: initial experience with 3-T imaging to allay venous contamination in the calf. [2008.12]
CONCLUSION: At 3-T MRI, a lower injection rate may alleviate venous contamination and increase arterial visibility in the calf while signal-to-noise and contrast-to-noise ratios at higher levels are maintained.
Clinical Trials Related to Ca-Dtpa (Pentetate)
Radiolabeled Monoclonal Antibody Therapy in Treating Adult Patients Who Have Recurrent Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma [Recruiting]
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver
cancer-killing substances to them without harming normal cells.
PURPOSE: This phase I/II trial is studying the side effects and best dose of radiolabeled
monoclonal antibody when given together with pentetic acid calcium and to see how well they
work in treating patients with recurrent Hodgkin's lymphoma or non-Hodgkin's lymphoma.
Trial of Concurrent Versus Sequential Tamoxifen With Radiotherapy in Breast Cancer Patients [Recruiting]
Two hundred and sixty patients with breast cancer will be accrued into the study. After
inclusion in the study, all the patients will be randomized into two arms. Arm 1 will
receive Tamoxifen given concurrently with radiotherapy while in Arm 2 radiotherapy will be
given followed by tamoxifen sequentially. The patients will be stratified for the following
factors: a) BCS (Breast conservative surgery) versus MRM (modified radical mastectomy) and
b) central lung distance (CLD) > 2 cm.
Patients in both arms will continue tamoxifen for a period of 5 years. The patients will be
evaluated by high-resolution computed tomography (HRCT) (baseline and at 2 years), serum
transforming growth factor (TGF) beta levels (baseline and at 6 months) and
diethylenetriaminepentaacetic acid (DTPA) aerosol clearance half life (baseline and at 6
months).
PneuMum: Pneumococcal Vaccination of Australian Indigenous Mothers [Recruiting]
PneuMum is a randomised controlled trial that aims to find out if pneumococcal vaccination
for Australian Indigenous mothers, in the last few months of pregnancy or at delivery, can
prevent ear disease in infants. Mothers will receive the 23 valent pneumococcal
polysaccharide vaccine (23vPPV) either: a) during the third trimester of pregnancy; b) soon
after child birth; or c) seven months after child birth (control group). The adult
diphtheria, tetanus and acellular pertussis vaccine (dTpa) will be used as the control
vaccine for the birth dose.
The study aims to recruit 210 Indigenous women aged 17-39 years who have an uncomplicated
pregnancy. Following recruitment, subjects will be randomly assigned to one of the three
groups.
Each mother and infant will be followed from pregnancy until the baby is seven months of
age. All routinely recommended vaccinations on the standard vaccination schedule will
continue to be offered by the subject's vaccine provider in accordance with current clinical
practice.
The primary outcome will be prevalence of middle ear disease at seven months of age, defined
as middle ear effusion or tympanic membrane perforation or acute otitis media. Pneumatic
otoscopy, video-otoscopy and tympanometry will be used in the ear examinations. The primary
analyses will be a direct comparison of the proportion of infants in the control group who
have nasopharyngeal carriage of one or more vaccine type pneumococci at seven months of age
compared to infants in each of the other two groups. A similar comparison of the proportion
with middle ear disease will be undertaken between the control group and the respective
intervention group.
|
